Literature DB >> 24338274

DNA promoter and histone H3 methylation downregulate NGX6 in gastric cancer cells.

Jian Liu1, Xinjiang Zhu, Xiaoyang Xu, Dongqiu Dai.   

Abstract

Nasopharyngeal carcinoma-associated gene 6 (NGX6) is a novel candidate tumor metastasis suppressor gene. Our study was to determine whether DNA hypermethylation and histone modification at the NGX6 gene promoter play important roles in silencing NGX6 expression in gastric cancer. NGX6 expression was downregulated in all gastric cancer cells and 76.19 % tissues. In three GC cell lines, hypermethylated NGX6 loci were characterized by histone H3-K9 hypoacetylation and hypermethylation. Trichostatin A treatment could moderately increase H3-K9 acetylation at the silenced loci; however, it had no effect on DNA and H3-K9 methylation and minimal effects on NGX6 expression. In contrast, 5'aza-2'-deoxycytidine treatment could rapidly decrease DNA and H3-K9 methylation at the silenced loci, leading to the reexpression of NGX6. Combined treatment with 5'aza-2'-deoxycytidine and trichostatin A had synergistic effects on the reexpression of NGX6 at the hypermethylation loci. Our current study shows that NGX6 expression is downregulated in GC cancer cells and tissues due to NGX6 promoter methylation and H3-K9 methylation, but not H3-K9 acetylation. Our findings indicate that the downregulation of NGX6 expression contributes to the development and progression of gastric cancer. More studies are needed to determine the precise mechanism of NGX6 in the progression of gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24338274     DOI: 10.1007/s12032-013-0817-z

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  36 in total

Review 1.  In vivo cross-linking and immunoprecipitation for studying dynamic Protein:DNA associations in a chromatin environment.

Authors:  M H Kuo; C D Allis
Journal:  Methods       Date:  1999-11       Impact factor: 3.608

2.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

3.  Partitioning and plasticity of repressive histone methylation states in mammalian chromatin.

Authors:  Antoine H F M Peters; Stefan Kubicek; Karl Mechtler; Roderick J O'Sullivan; Alwin A H A Derijck; Laura Perez-Burgos; Alexander Kohlmaier; Susanne Opravil; Makoto Tachibana; Yoichi Shinkai; Joost H A Martens; Thomas Jenuwein
Journal:  Mol Cell       Date:  2003-12       Impact factor: 17.970

4.  Isolation and characterization of a novel cDNA, UBAP1, derived from the tumor suppressor locus in human chromosome 9p21-22.

Authors:  J Qian; J Yang; X Zhang; B Zhang; J Wang; M Zhou; K Tang; W Li; Z Zeng; X Zhao; S Shen; G Li
Journal:  J Cancer Res Clin Oncol       Date:  2001-10       Impact factor: 4.553

5.  Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2'-deoxycytidine.

Authors:  Carvell T Nguyen; Daniel J Weisenberger; Mihaela Velicescu; Felicidad A Gonzales; Joy C Y Lin; Gangning Liang; Peter A Jones
Journal:  Cancer Res       Date:  2002-11-15       Impact factor: 12.701

6.  Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype.

Authors:  M Toyota; N Ahuja; H Suzuki; F Itoh; M Ohe-Toyota; K Imai; S B Baylin; J P Issa
Journal:  Cancer Res       Date:  1999-11-01       Impact factor: 12.701

7.  NGX6 inhibits cell invasion and adhesion through suppression of Wnt/beta-catenin signal pathway in colon cancer.

Authors:  Qin Guo; Shourong Shen; Mantian Liao; Ping Lian; Xiaoyan Wang
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2010-06-13       Impact factor: 3.848

Review 8.  The epigenomics of cancer.

Authors:  Peter A Jones; Stephen B Baylin
Journal:  Cell       Date:  2007-02-23       Impact factor: 41.582

9.  Dependence of histone modifications and gene expression on DNA hypermethylation in cancer.

Authors:  Jill A Fahrner; Sayaka Eguchi; James G Herman; Stephen B Baylin
Journal:  Cancer Res       Date:  2002-12-15       Impact factor: 12.701

10.  Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation.

Authors:  Satoshi Fujii; Kosei Ito; Yoshiaki Ito; Atsushi Ochiai
Journal:  J Biol Chem       Date:  2008-04-22       Impact factor: 5.157

View more
  6 in total

1.  Association of ultrasonographic features with NGX6 expression and prognosis in invasive ductal breast carcinoma.

Authors:  Jidong Xiao; Yuanquan Zhou; Wenhui Zhu
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

2.  The FENDRR/miR-214-3P/TET2 axis affects cell malignant activity via RASSF1A methylation in gastric cancer.

Authors:  Zhaocai He; Xin Wang; Changhao Huang; Yu Gao; Chen Yang; Pengwei Zeng; Zihua Chen
Journal:  Am J Transl Res       Date:  2018-10-15       Impact factor: 4.060

3.  Down-regulation of BRMS1 by DNA hypermethylation and its association with metastatic progression in triple-negative breast cancer.

Authors:  Bin Kong; Zhi-Dong Lv; Yu Wang; Li-Ying Jin; Lei Ding; Zhao-Chuan Yang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

Review 4.  Tumor suppressor NGX6 inhibits the growth and metastasis of multiple cancers.

Authors:  Shiwei He; Yancheng Zhong; Cijun Shuai; Dan Gao; Pingpin Wei; Guiyuan Li; Shuping Peng
Journal:  Tumour Biol       Date:  2016-02-15

5.  Long noncoding RNA-LET, which is repressed by EZH2, inhibits cell proliferation and induces apoptosis of nasopharyngeal carcinoma cell.

Authors:  Qiuzhen Sun; Hongbing Liu; Lihua Li; Shaorong Zhang; Ke Liu; Yuehui Liu; Chunping Yang
Journal:  Med Oncol       Date:  2015-08-05       Impact factor: 3.064

6.  Clinical significance of epigenetic silencing and re-expression of O6-methylguanine-DNA methyltransferase using epigenetic agents in laryngeal carcinoma.

Authors:  Jing Yang; Xin-Bing Zhu; Li-Xia He; Zhao-Wei Gu; Ming-Zhu Jin; Wen-Yue Ji
Journal:  Oncol Lett       Date:  2014-11-03       Impact factor: 2.967

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.